Botanical and Plant-Derived Drugs: Global Markets

Botanical and Plant-Derived Drugs: Global Markets

This report:

• Identifies and classifies the plant-derived drugs that have been commercialized to date
  
  
• Contains forecasts for the global volume and value of plant-derived drug shipments and their markets through 2013
  
  
• Analyzes the historical and current volume and value of shipments of each of these drugs in specified geographical markets
  
  
• Identifies and evaluates the impact of factors that will drive future demand for plant-derived drugs
  
  
• Describes plant-derived drugs that are currently in the clinical testing or approvals stage and assesses the probability that they will be commercialized successfully in the next 5 years
  
  
• Profiles the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years.

CHAPTER 1: INTRODUCTION

STUDY BACKGROUND

STUDY GOAL AND OBJECTIVES

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY AND INFORMATION SOURCES

COMMERCIAL DRUGS

DEVELOPMENTAL DRUGS

TABLE 1 FDA APPROVAL PROCESS FOR NEW DRUGS

ANALYST CREDENTIALS

RELATED BCC PUBLICATIONS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER 2: SUMMARY

SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

CHAPTER 3: OVERVIEW

BRIEF HISTORY OF PLANT-DERIVED MEDICINES

BRIEF HISTORY OF PLANT-… (CONTINUED)

TABLE 2 KEY DATES IN BOTANICAL MEDICINE

TABLE 3 WELL KNOWN PLANT-DERIVED DRUGS

OPPORTUNITY LIES BEYOND WHAT’S KNOWN

FIGURE 1 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000-2005)* (%)

KEY DRIVERS

KEY CHALLENGES

SIGNS OF INDUSTRY INVESTMENT

TABLE 4 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 5 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS

BOTANICAL DRUGS DEFINED

UNDERSTANDING THE REGULATORY PROCESS

TABLE 6 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY

THE FIRST APPROVED BOTANICAL

A GROWING PIPELINE

FIGURE 2 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)

OVERALL PHARMA LANDSCAPE

TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)

MAJOR CLASSES OF PLANT DRUGS

Terpenes and Steroids

Terpenes

Steroids

Alkaloids and Glycosides

Alkaloids

Ergot Alkaloids

Morphine Alkaloids

Vinca Alkaloids

Glycosides

Cardiac Glycosides

Anthraglycosides

Phenols

E. Cava Algae

Flavonoids

Resveratrol

Coumarin

Catechins

Proanthocyanidins

INTELLECTUAL PROPERTY

PRODUCTION

MOVING PRODUCTION FORWARD

ARTEMISININ: A CASE STUDY

SUPPLY AND LEGAL ISSUES

TABLE 8 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS

DRUG DEVELOPMENT AND MANUFACTURE

TABLE 9 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES

CHAPTER 4: MARKET SEGMENTATION

GEOGRAPHIC SEGMENTATION

SALES OF PLANT-DERIVED DRUGS BY REGION

TABLE 10 PLANT-DERIVED DRUG SALES FORECAST BY REGION, THROUGH 2013 (% TOTAL SALES)

FIGURE 3 GEOGRAPHIC SEGMENTATION FOR PLANT-DERIVED DRUGS, 2008 AND 2013 (%)

THERAPEUTIC AREA SEGMENTATION

NUMBER OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA

TABLE 11 FDA APPROVED BOTANICAL DRUGS FORECAST THROUGH 2013 (UNITS)

FIGURE 4 COMPOSITION OF FDA APPROVED BOTANICAL INDICATION FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)*

Value of Plant-Derived Drugs by Therapeutic Area

TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPUETIC AREA, THROUGH 2013 ($ MILLIONS)

FIGURE 5 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)

CHAPTER 5: THERAPEUTIC AREAS IN DETAIL FOR PLANT-DERIVED AND BOTANICAL DRUGS, THROUGH 2013

HORMONE THERAPY AND